MA52809A - Inhibiteurs de sarm1 - Google Patents
Inhibiteurs de sarm1Info
- Publication number
- MA52809A MA52809A MA052809A MA52809A MA52809A MA 52809 A MA52809 A MA 52809A MA 052809 A MA052809 A MA 052809A MA 52809 A MA52809 A MA 52809A MA 52809 A MA52809 A MA 52809A
- Authority
- MA
- Morocco
- Prior art keywords
- sarm1 inhibitors
- sarm1
- inhibitors
- Prior art date
Links
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 title 1
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682045P | 2018-06-07 | 2018-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52809A true MA52809A (fr) | 2021-04-14 |
Family
ID=68770684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052809A MA52809A (fr) | 2018-06-07 | 2019-06-06 | Inhibiteurs de sarm1 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220194933A1 (fr) |
| EP (1) | EP3801499B1 (fr) |
| JP (1) | JP7478142B2 (fr) |
| CN (1) | CN112839648B (fr) |
| CA (1) | CA3102598A1 (fr) |
| ES (1) | ES2988933T3 (fr) |
| MA (1) | MA52809A (fr) |
| WO (1) | WO2019236884A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| MA52813A (fr) | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| US12083114B2 (en) | 2018-12-19 | 2024-09-10 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 in combination with neuro-protective agents |
| TW202134436A (zh) * | 2019-11-26 | 2021-09-16 | 美商達薩瑪治療公司 | 用於神經保護之方法及組成物 |
| JP7478252B2 (ja) | 2020-04-09 | 2024-05-02 | ディスアーム セラピューティクス, インコーポレイテッド | Sarm1の阻害剤 |
| CA3174320A1 (fr) * | 2020-04-09 | 2021-10-14 | Jonathan Bentley | Derives de pyrazole condenses utiles en tant qu'inhibiteurs de sarm1 |
| TW202334117A (zh) * | 2020-08-24 | 2023-09-01 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
| KR20250121164A (ko) * | 2022-11-12 | 2025-08-11 | 캠브리지 엔터프라이즈 리미티드 | 치료법 및 화장품에 사용하기 위한 sarm1 제제 |
| WO2024222835A1 (fr) * | 2023-04-27 | 2024-10-31 | Sironax Ltd. | Modulateurs de sarm1, préparations et leurs utilisations |
| CN116836162B (zh) * | 2023-05-24 | 2025-09-05 | 南方医科大学 | 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA847926B (en) * | 1983-10-17 | 1986-05-28 | Lilly Co Eli | 3-bicyclicpyridinium-methyl cephalosporins |
| US5468757A (en) * | 1994-01-31 | 1995-11-21 | Eli Lilly And Company | 6-azaindole thromboxane synthase inhibitors |
| CA2348734A1 (fr) * | 1998-10-30 | 2000-05-11 | Merck & Co., Inc. | Inhibiteurs de la thrombine |
| WO2002083175A1 (fr) * | 2001-04-11 | 2002-10-24 | Senju Pharmaceutical Co., Ltd. | Agents ameliorant la fonction visuelle |
| US7557103B2 (en) * | 2005-04-05 | 2009-07-07 | Eli Lilly And Company | Imidazopyridazine compounds |
| WO2009041567A1 (fr) * | 2007-09-27 | 2009-04-02 | Banyu Pharmaceutical Co., Ltd. | Dérivè de diaryl kétimine à activité antagoniste sur le récepteur de l'hormone de concentration de la mélanine |
| US8518952B2 (en) * | 2008-08-06 | 2013-08-27 | Pfizer Inc. | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors |
| CA2780922A1 (fr) * | 2010-02-11 | 2011-08-18 | OSI Pharmaceuticals, LLC | Derives de la 7-aminofuropyridine |
| DE102011009961A1 (de) * | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| CA2825599C (fr) * | 2011-02-01 | 2021-07-13 | The Board Of Trustees Of The University Of Illinois | Composes 4-methyl-n-hydroxybenzamide comme inhibiteurs d'histone deacetylase (hdac) |
| GB201310460D0 (en) * | 2013-06-12 | 2013-07-24 | Lytix Biopharma As | Compounds |
| CN106456605A (zh) * | 2014-02-25 | 2017-02-22 | 艾其林医药公司 | 用于治疗补体介导的疾病的氨基化合物 |
| EP3481391A4 (fr) * | 2016-07-11 | 2020-03-11 | Lifesci Pharmaceuticals, Inc. | Composés inhibiteurs thérapeutiques |
| EP3515426A1 (fr) | 2016-09-24 | 2019-07-31 | Washington University | Inhibiteurs de l'activité sarm1 nadase et utilisations de ceux-ci |
| US10323036B2 (en) * | 2016-10-14 | 2019-06-18 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
-
2019
- 2019-06-06 ES ES19814860T patent/ES2988933T3/es active Active
- 2019-06-06 US US16/972,660 patent/US20220194933A1/en active Pending
- 2019-06-06 CN CN201980052476.0A patent/CN112839648B/zh active Active
- 2019-06-06 WO PCT/US2019/035839 patent/WO2019236884A1/fr not_active Ceased
- 2019-06-06 CA CA3102598A patent/CA3102598A1/fr active Pending
- 2019-06-06 EP EP19814860.3A patent/EP3801499B1/fr active Active
- 2019-06-06 MA MA052809A patent/MA52809A/fr unknown
- 2019-06-06 JP JP2021518046A patent/JP7478142B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3801499A4 (fr) | 2022-01-12 |
| ES2988933T3 (es) | 2024-11-22 |
| WO2019236884A1 (fr) | 2019-12-12 |
| EP3801499B1 (fr) | 2024-02-28 |
| JP7478142B2 (ja) | 2024-05-02 |
| CA3102598A1 (fr) | 2019-12-12 |
| JP2021528488A (ja) | 2021-10-21 |
| CN112839648B (zh) | 2025-04-04 |
| EP3801499A1 (fr) | 2021-04-14 |
| US20220194933A1 (en) | 2022-06-23 |
| CN112839648A (zh) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54543A (fr) | Inhibiteurs de kif18a | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| IL269196A (en) | Novel inhibitors | |
| EP3843714A4 (fr) | Inhibiteurs de cd73 | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| DK3740479T3 (da) | Dna-pk-hæmmere | |
| EP3788042A4 (fr) | Inhibiteurs de bcl-2 | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| EP3846674C0 (fr) | Spéculum vaginal | |
| MA53287A (fr) | Inhibiteurs de prmt5 | |
| MA52635A (fr) | Inhibiteurs de magl | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| IL304348A (en) | Cd73 inhibitors | |
| PT3746446T (pt) | Inibidores de prc2 | |
| EP3801500A4 (fr) | Inhibiteurs de sarm1 | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| EP3786157A4 (fr) | Inhibiteur de l'interaction protéine-protéine mll1-wdr5 de phényle triazole | |
| EP3805381A4 (fr) | Phytase mutée | |
| EP3784463A4 (fr) | Fluorosulfones | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| EP3760247A4 (fr) | Séparateur de toxines | |
| EP3706742A4 (fr) | Inhibiteurs de prmt5 | |
| EP3833664A4 (fr) | Inhibiteurs de smad3 |